---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-003984"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2024-01-26T23:59:59+00:00"
generated_at: "2026-06-06T16:28:50.213419+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dare Bioscience announces CFO retirement, CCO resignation, board downsizing

## Summary
- CFO Lisa Walters-Hoffert retired effective Jan. 26, 2024; will consult for 9 months at $31,667/month.
- CCO John Fair resigns effective June 30, 2024; part-time from Apr. 1; no replacement planned.
- MarDee Haring-Layton appointed Chief Accounting Officer; CEO Johnson will serve as principal financial officer.
- Board to shrink from 8 to 6; directors Blanchard and Ononye-Onyia to resign before 2024 annual meeting.
- Non-employee director cash compensation reduced to 25th percentile of peer group.

## SEC filing metadata
- accession: 0001493152-24-003984
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2024-01-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315224003984/0001493152-24-003984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315224003984/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-003984
- JSON: https://secwatch.observer/filing/0001493152-24-003984.json
- Plain text: https://secwatch.observer/filing/0001493152-24-003984.txt

## Key facts
- Executive change
  John Fair resigned as Chief Commercial Officer at Dare Bioscience, Inc..
  - Action: resigned
  - Role: Chief Commercial Officer
  source text: On January 24, 2024, John Fair, our Chief Commercial Officer, informed us that, in light of the full-scale commercial launch of XACIATO TM —bringing to fruition one of his primary responsibilities as Chief Commercial Officer—he will be resigning from all positions with us and his employment with us will end effective June 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315224003984/0001493152-24-003984-index.htm
- Executive change
  MarDee Haring-Layton was appointed as Chief Accounting Officer at Dare Bioscience, Inc..
  - Action: appointed
  - Role: Chief Accounting Officer
  source text: Ms. Haring-Layton, our current Vice President, Accounting & Finance, was appointed as our Chief Accounting Officer and will serve as our principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315224003984/0001493152-24-003984-index.htm
- Executive change
  Lisa Walters-Hoffert retired as Chief Financial Officer at Dare Bioscience, Inc..
  - Action: retired
  - Role: Chief Financial Officer
  source text: On January 23, 2024, Lisa Walters-Hoffert informed Daré Bioscience, Inc. (“our,” “we”, “us,” “our,” or the “Company”) that she will retire from all positions with the Company, and her employment with the Company will end, effective January 26, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315224003984/0001493152-24-003984-index.htm
- Executive change
  Sabrina Martucci Johnson changed role as Chief Executive Officer and President at Dare Bioscience, Inc..
  - Action: will serve as principal financial officer
  - Role: Chief Executive Officer and President
  source text: Ms. Johnson, our Chief Executive Officer and President, will serve as our principal financial officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315224003984/0001493152-24-003984-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.